IRLA
IRulya Therapeutics Inc.
IRLA | NASDAQ
$31.90
-$1.05 (-3.19%)
Nov 2, 2026, 12:46 PM ET · Market open
Market Data
Market Cap $32.44M
Enterprise Value $-82.47M
Beta 1.33
Average Volume 47.73K
Shares Outstanding (Diluted) 6.13M
Shares Change YoY 2527.26%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US22053A3059
Price Performance
Price Change 1M 9.3%
Price Change 3M 27.8%
Price Change 6M 30.7%
Price Change YTD -95.2%
Price Change 1Y -90.2%
Price Change 3Y -83.1%
Price Change 5Y -99.0%
1M CAGR (ann.) 11.8%
1Y CAGR (ann.) -90.2%
5Y CAGR (ann.) -69.2%
All-Time CAGR -50.7%
Valuation
PE Ratio -0.48
Forward PE N/A
PEG Ratio -0.02
Forward PEG 0.00
PS Ratio N/A
Forward PS N/A
PB Ratio 0.31
P/FCF Ratio -0.71
P/Adj. FCF Ratio -0.53
P/OCF Ratio -4.31
EV/Sales N/A
EV/EBIT 1.14
EV/EBITDA 1.14
EV/FCF 1.75
Earnings Yield -209.1%
FCF Yield -140.3%
Adj. FCF Yield -187.5%
Financial Health
Net Cash $115.98M
Total Debt $0
Cash & Short-Term Investments $115.98M
Total Assets $124M
Current Ratio 14.52
Quick Ratio 14.52
Debt / Equity Ratio 0.00
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage 0.00
Altman Z-Score -5.16
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -33.7%
Returns
Return on Assets -74.6%
Return on Equity -413.3%
Return on Invested Capital -104.6%
Return on Capital Employed -107.1%
Return on Tangible Assets -74.6%
Historical Growth (CAGR)
Revenue CAGR 3Y N/A
Revenue CAGR 5Y N/A
Revenue CAGR 10Y N/A
EPS CAGR 3Y 51.3%
EPS CAGR 5Y 36.2%
EPS CAGR 10Y N/A
FCF CAGR 3Y -25.5%
FCF CAGR 5Y 4.2%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 3
EPS Growth Next 3Y 31.1%
Revenue Growth Next 3Y N/A
Earnings Date Nov 11, 2026
EPS Estimate (next Q) -$1.39
EPS Growth Est (next Q) -97.2%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $70.00
Price Target Upside 112.4%
Cash Flow
Operating Cash Flow $-46.92M
Free Cash Flow $-47M
Adj. Free Cash Flow $-62.83M
FCF Per Share -$7.66
OCF Per Share -$7.65
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $-36K
Operating Income $-123.68M
EBITDA $-72.29M
Net Income $-92.48M
EPS (Diluted) -$68.91
Revenue / Employee N/A
Profit / Employee $-2.43M
Employees 38
Add to Watchlist
Select watchlists to add or remove IRLA